CervoMed (CRVO) Retained Earnings (2010 - 2026)
CervoMed (CRVO) posted Retained Earnings of -$105.7 million for Q1 2026, down 191.19% sequentially from $115.9 million in Q4 2025, and down 195.89% YoY from $110.2 million in Q1 2025.
CervoMed (CRVO) Retained Earnings (2010 - 2026) Analysis & Trends
CervoMed has reported Retained Earnings for 17 years, with the latest figure at -$105.7 million in Q1 2026.
- Quarterly Retained Earnings fell 195.89% year-over-year to -$105.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$105.7 million (down 195.89% YoY) and the FY2025 annual result came in at $115.9 million, up 5.49% from the prior year.
- Retained Earnings declined to -$105.7 million in Q1 2026 per CRVO's latest filing, from $115.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at $115.9 million in Q4 2025 and troughed at -$105.7 million in Q1 2026.
- A 5-year average of $23.5 million and a median of -$19702.0 in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings jumped 70995.2% in 2023, then plunged 415512.23% in 2025.
- Over 5 years, Retained Earnings stood at -$52.3 million in 2022, then surged by 218.26% to $61.8 million in 2023, then soared by 77.75% to $109.9 million in 2024, then rose by 5.49% to $115.9 million in 2025, then plunged by 191.19% to -$105.7 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$105.7 million, $115.9 million, and $115.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | 135.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 135.18 Mn |
| Mar 31, 2026 | -105.70 Mn |
| Dec 31, 2025 | 115.91 Mn |
| Sep 30, 2025 | 115.61 Mn |
| Jun 30, 2025 | -81.88 Mn |
| Mar 31, 2025 | 110.23 Mn |
| Dec 31, 2024 | 109.87 Mn |
| Sep 30, 2024 | 109.53 Mn |
| Jun 30, 2024 | -19,702.00 |
| Mar 31, 2024 | 62.29 Mn |
| Dec 31, 2023 | 61.81 Mn |
| Sep 30, 2023 | 61.65 Mn |
| Jun 30, 2023 | -54.23 Mn |
| Mar 31, 2023 | -52.80 Mn |
| Dec 31, 2022 | -52.27 Mn |
| Sep 30, 2022 | -86,955.00 |
| Jun 30, 2022 | -86,583.00 |
| Mar 31, 2022 | -49,658.00 |
| Dec 31, 2021 | -130.01 Mn |
| Sep 30, 2021 | -126.53 Mn |